Key Developments: Anika Therapeutics Inc (ANIK.O)
17 May 2013
Latest Key Developments (Source: Significant Developments)
Anika Therapeutics Inc announced that for fiscal 2013, it expects solid growth in top and bottom lines. According to I/B/E/S estimates, analysts are expecting the Company to report revenue of $78 million and EPS of $0.91 for fiscal 2013. Full Article
Anika Therapeutics Inc announced the appointment of Sylvia Cheung as the Company`s Chief Financial Officer, effective April 1, 2013. Cheung, who has served as Anika`s Vice President for Strategic Processes since February 2012, will succeed Kevin W. Quinlan, who is leaving Anika effective March 31, 2013 to pursue other professional opportunities. Full Article
Anika Therapeutics Inc Issues Q4 2012 Revenue Guidance Above Estimates; Revises FY 2012 Revenue Guidance To A Range Above Estimates; Sees FY 2012 Earnings Guidance In Line Or Exceed Prior Range
Anika Therapeutics Inc announced that based on preliminary unaudited information and subject to the year-end accounting close and audit, the Company expects total revenue for the fourth quarter 2012 in the range of $22.0-$23.0 million. For fiscal 2012, total revenue is expected to be between $70.0 million and $71.6 million. The Company expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share for fiscal 2012. This includes, as announced on December 28, 2012, a pre-tax charge of approximately $2.5 million related to the closure of the Company’s tissue engineering facility in Abano Terme, Italy. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $69 million and EPS of $0.74 for fiscal 2012; revenue of $20.5 million for the fourth quarter of 2012. Full Article
Anika Therapeutics Inc announced that for fiscal 2012 it expect to be in the range of $70 million in revenue and $0.74 for EPS. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $69 million and EPS of $0.78 for fiscal 2012. Full Article
Anika Therapeutics, Inc. announced that for fiscal 2012, it expects to grow revenue and earnings per share (EPS) by greater than 20%. The Company reported revenue of $64.78 million and EPS of $0.62 in fiscal 2011. According to I/B/E/S estimates, analysts are expecting the Company to report revenue of $73 million and EPS of $0.86 for fiscal 2012. Full Article
Anika Therapeutics, Inc. Announces U.S. MONOVISC License And Supply Agreement With DePuy Mitek, Inc.
Anika Therapeutics, Inc. announced the signing of an exclusive, multi-year U.S. licensing and supply agreement with DePuy Mitek, Inc., a orthopedic sports medicine company, for Anika’s MONOVISC, a purified, high molecular weight form of hyaluronic acid for treating pain in patients suffering from osteoarthritis of the knee. In connection with the entering into of the agreement, Anika will receive an initial payment of $2.5 million. Anika also will be entitled to receive additional payments from DePuy Mitek, following the mutual decision to launch the product, related to future regulatory, clinical, and sales milestones. Full Article
Misonix, Inc. Announces Exclusive U.S. Distribution Agreement For Wound Care Product With Anika Therapeutics, Inc.'s Anika Therapeutics S.r.l.
Misonix, Inc. announced a new five year exclusive U.S. distribution agreement with Anika Therapeutics S.r.l., a wholly owned subsidiary of Anika Therapeutics, Inc., a Company in products for tissue protection, healing, and repair. Misonix will sell and distribute Anika's Hyalomatrix product, a skin substitute based on hyaluronic acid technology. Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds and will be a companion product for Misonix's SonicOne Ultrasonic Wound Cleansing and Debridement System. Anika will manufacture and supply finished product to Misonix, while Misonix will be responsible for all aspects of commercialization in the United States. Full Article